uploads///Interferons

Biogen’s Fampyra and Interferons in 1Q18

By

Apr. 26 2018, Updated 7:31 a.m. ET

Fampyra revenue trends

In 1Q18, Biogen’s (BIIB) Fampyra generated revenues of $24 million compared to $20 million in 1Q17. That reflected ~19% growth on a year-over-year (or YoY) basis and 1% growth quarter-over-quarter.

Article continues below advertisement

Interferons: Revenue trends

In 1Q18, Biogen’s interferons reported net revenues of $550 million compared to $648 million in 1Q17, which reflected a ~15% decline on a year-over-year (or YoY) basis and a ~15% decline quarter-over-quarter.

Biogen’s interferons for the treatment of multiple sclerosis include Avonex and Plegridy. In 1Q18, Biogen’s interferons benefited $11 million due to changes in foreign exchange rates.

Avonex: Revenue trends

In 1Q18, Biogen’s interferon Avonex for the treatment of multiple sclerosis generated revenues of $451 million compared to $537 million in 1Q17. That reflected a ~16% YoY decline and a ~13% decline quarter-over-quarter.

In 1Q18 in the US and international markets, Avonex generated revenues of $324 million and $127 million, respectively, compared to $400 million and $136 million, respectively, in 1Q17. That’s a ~19% and ~7% YoY decline, respectively.

In 1Q18 in the US and international markets, Avonex’s revenues witnessed a ~14% and ~12% decline, respectively, on a quarter-over-quarter basis.

Plegridy revenue trends

In 1Q18, Biogen’s interferon Plegridy reported revenues of $100 million compared to $112 million in 1Q17, which reflected an ~11% YoY decline and a ~20% decline quarter-over-quarter.

In 1Q18 in the US and international markets, Plegridy generated revenues of $47 million and $52 million, respectively, compared to $65 million and $47 million, respectively, in 1Q17. That reflected a ~27% decline and an ~11% growth, respectively, on a YoY basis.

In 1Q18 in the US and international markets, Plegridy’s revenues witnessed a ~36% decline and a ~3% growth, respectively, on a quarter-over-quarter basis.

In the multiple sclerosis injectable medications market, Biogen’s interferons face stiff competition from Teva Pharmaceutical’s (TEVA) Copaxone, Novartis’s (NVS) Extavia and Glatopa, and Merck & Co.’s (MRK) Rebif.

Advertisement

More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.